NCT02934698View on ClinicalTrials.gov

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

PHASE3CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

Ivacaftor

Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.

All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Medical University of South Carolina

OTHER

NCT02934698 - An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations | Biotech Hunter | Biotech Hunter